Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate

In science and medicine, information is constantly changing and may become out-of-date as new data emerge. All articles and interviews are informational only, should never be considered medical advice, and should never be acted on without review with your health care team.

This is not CLL/SLL specific. But wouldn’t any immunocompromised (IC) patient feel safer if they knew there was a five-day course of an oral anti-viral medication PAXLOVID™ (PF-07321332; ritonavir), that when taken early after contracting COVID-19 gave a nine out of ten chance of preventing hospitalization and death?

That dream moved closer to a reality today with the Emergency Use Authorization (EUA) submission by Pfizer for PAXLOVID™ (PF-07321332; ritonavir).

With promising antibodies active for pre-exposure prophylaxis (PreP) and potent therapeutics close to becoming accessible, the world may soon feel a bit safer for those with chronic lymphocytic leukemia/small lymphocytic lymphoma, as well as others who are immunocompromised.

Here is Pfizer’s press release.

Stay strong. We are all in this together.

Brian Koffman MDCM (retired) MS Ed
Co-Founder, Executive VP, and Chief Medical Officer
CLL Society, Inc.